Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Inclusion Criteria:

- Must be able to provide written informed consent before any screening procedures.

- Male or female patients ≥18 years of age.

- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

- Patients with a confirmed diagnosis of multiple myeloma who have received two or more
lines of therapy including an IMiD and PI, and are relapsed and/or refractory to their
most recent line of therapy. Patients who have received a prior autologous bone marrow
transplant and otherwise meet the inclusion criteria are eligible for this study.

- Must have measurable disease defined by at least 1 of the following 3 measurements:

- Serum M-protein ≥ 0.5 g/dL OR

- Urine M-protein ≥ 200 mg/24 hours OR

- Serum free light chain (FLC) > 100 mg/L of involved FLC

- All patients must be willing to undergo a mandatory serial bone marrow aspirate and/or
biopsy at screening and subsequently following treatment for the assessment of
biomarker/pharmacodynamics and disease status. Exceptions may be considered after
documented discussion with Novartis.

Other inclusion criteria included in the protocol might apply.

Exclusion Criteria:

- Use of systemic chronic steroid therapy (≥10mg /day of prednisone or equivalent), or
any immunosuppressive therapy within 7 days of first dose of study treatment. Topical,
inhaled, nasal, or ophthalmic steroids are allowed.

- Malignant disease, other than that being treated in this study. Exceptions to this
exclusion include the following: malignancies that were treated curatively and have
not recurred within 2 years prior to study treatment; completely resected basal cell
and squamous cell skin cancers, and completely resected carcinoma in situ of any type.

- Active, known or suspected autoimmune disease other than patients with vitiligo,
residual hypothyroidism only requiring hormone replacement, psoriasis not requiring
systemic treatment or conditions not expected to recur.

- Patients with prior known toxicity attributed to PD-1 or PDL-1 directed therapy, which
led to discontinuation of these agents, will be excluded from the PDR001 containing
arms of the study.

- Patients with prior known toxicity from IL-17A directed therapy, which led to
discontinuation of the study treatment, will be excluded from CJM112 containing arms
of the study.

- Any of the following clinical laboratory results during screening (i.e., within 28
days before the first dose of study treatment):

- Absolute neutrophil count (ANC) < 1,000/mm3 without growth factor support within
7 days prior to testing

- Platelet count < 75,000 mm3 without transfusion support within 7 days prior to
testing

- Bilirubin > 1.5 times the upper limit of the normal range (ULN)

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the
ULN

- Calculated creatinine clearance < 30 ml/min according to Cockcroft-Gault equation
Other exclusion criteria included in the protocol might apply.